Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
BCAX
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
globenewswire.com
7 hours ago
seekingalpha.com
9 hours ago
globenewswire.com
16 hours ago
globenewswire.com
16 hours ago
Earnings Growth
YoY
Current
Estimates
Q3.23
N/A
NA
vs NA
Q4.23
N/A
NA
vs NA
Q1.24
N/A
-0.27
vs -0.15
Q2.24
N/A
-0.27
vs -0.15
Q3.24
N/A
-1.60
vs -0.42
Q4.24
N/A
-0.39
vs -0.23
Q1.25
N/A
-0.68
vs -0.27
Q2.25
N/A
-0.50
vs -0.27
Q3.25
N/A
-0.54
vs -1.60
Q4.25
N/A
-0.56
vs -0.39
Sales Growth
YoY
Current
Estimates
Q1.23
NA
NA vs NA
Q2.23
NA
NA vs NA
Q3.23
NA
NA vs NA
Q4.23
NA
NA vs NA
Q1.24
NA
NA vs NA
Q2.24
NA
NA vs NA
Q3.24
NA
NA vs NA
Q4.24
NA
NA vs NA
Q1.25
NA
NA vs NA
Q2.25
NA
NA vs NA
Return on Equity
QoQ
Q1.23
NA
NA
vs NA
Q2.23
NA
NA
vs 0.48
Q3.23
NA
NA
vs NA
Q4.23
+8%
0.08
vs NA
Q1.24
-8%
-0.08
vs 0.08
Q2.24
+8%
0.08
vs -0.08
Q3.24
-3%
-0.03
vs 0.08
Q4.24
-4%
-0.04
vs -0.03
Q1.25
-8%
-0.08
vs -0.04
Q2.25
-6%
-0.06
vs -0.08
Institutionnal Ownership
QoQ
Q1.23
NA
NA
vs NA
NA
Q2.23
NA
NA
vs NA
NA
Q3.23
NA
NA
vs NA
NA
Q4.23
NA
NA
vs NA
NA
Q1.24
NA
NA
vs NA
NA
Q2.24
NA
NA
vs NA
NA
Q3.24
68
68
vs NA
NA
Q4.24
81
81
vs 68
19%
Q1.25
88
88
vs 81
9%
Q2.25
105
105
vs 88
19%
Quote Panel
Key Metrics
Relative Strength
BCAX
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
2026-Revenue
-15%2026-EPS
2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
40.00(119.18%)
Number of analyst
1
Last analyst upgrade/downgrade
Piper Sandler
initialisePrevious: Not converted
2025-08-18
Now: Overweight
Wells Fargo
upgradePrevious: Not converted
2025-05-23
Now: Underweight
Cantor Fitzgerald
initialisePrevious: Not converted
2024-10-08
Now: Overweight
Cowen & Co.
initialisePrevious: Not converted
2024-10-08
Now: Buy
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.
NASDAQ
Unprofitable
Unprofitable
-0.43Â ( -2.30%)
Relative Strenght
69
Volume Buzz
-14%
Earning Acce
No
Dist 52w H.
35%